Compare HUIZ & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | KTTA |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 18.1M |
| IPO Year | 2019 | N/A |
| Metric | HUIZ | KTTA |
|---|---|---|
| Price | $1.69 | $0.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.30 | ★ $3.00 |
| AVG Volume (30 Days) | 6.3K | ★ 312.7K |
| Earning Date | 06-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.58 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.28 |
| 52 Week High | $4.16 | $2.06 |
| Indicator | HUIZ | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 37.76 |
| Support Level | $1.19 | $0.42 |
| Resistance Level | $1.35 | $0.52 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 41.35 | 21.94 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.